Overview

Efficacy and Safety of CUSA-081 in the Restoration of Central Venous Access Device (CVAD) Functionality

Status:
Recruiting
Trial end date:
2022-09-01
Target enrollment:
Participant gender:
Summary
Study to evaluate the efficacy and safety of CUSA-081 in the restoration of central venous access device (CVAD) functionality in participants 18 years and older.
Phase:
Phase 3
Details
Lead Sponsor:
Chiesi Farmaceutici S.p.A.
Chiesi USA
Treatments:
Reteplase
Tissue Plasminogen Activator